Neoadjuvant Chemotherapy

Phase 3Small molecule

JJapan Clinical Oncology Group

Neoadjuvant Chemotherapy is one of 470 small molecule programs targeting Breast Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

469

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerNot yet recruiting

Ovarian CancerNot yet recruiting

Pancreas CancerRecruiting

DeliriumActive, not recruiting

Small Cell Lung CancerActive, not recruiting

Epithelial Ovarian CancerRecruiting

Pancreatic Ductal Adenocarcinoma (PDAC)Recruiting

Malignant NeoplasmRecruiting

Gastric AdenocarcinomaNot yet recruiting

ProspectiveEnrolling by invitation

Breast CancerPhase 2

Not yet recruiting

Ovarian CancerPhase 3

Not yet recruiting

Pancreas CancerPhase 3

Recruiting

DeliriumPreclinical

Active, not recruiting

Small Cell Lung CancerPreclinical

Active, not recruiting

Epithelial Ovarian CancerPreclinical

Recruiting

Pancreatic Ductal Adenocarcinoma (PDAC)Phase 2

Recruiting

Malignant NeoplasmPhase 2

Recruiting

Gastric AdenocarcinomaPhase 2

Not yet recruiting

ProspectivePreclinical

Enrolling by invitation

Showing 10 of 22 indications

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Neoadjuvant Chemotherapy

JJapan Clinical Oncology Group

Phase 3

12 2

Rilvegostomig

AstraZeneca

Preclinical

1 3

Ablavar

LLantheus Medical Imaging

Preclinical

2 4

Recombinant Human Endostatin

PPeking University Third Hospital

Preclinical

1 5

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 6

Lapatinib Plus Capecitabine

GSK

Preclinical

2 7

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 8

Combination NRT

UUniversity of Alabama at Birmingham

Preclinical

1 9

Calendula

OOHSU Knight Cancer Institute

Preclinical

1 10

Maxigesic

YYonsei University

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

PreclinicalRecruiting

Epithelial Ovarian Cancer

NCT06386887

Phase 2Active, not recruiting

Hepatocellular Carcinoma

NCT06524466

Phase 3Recruiting

Colon Cancer

NCT05194878

Q2 2027

Phase 2Recruiting

Chemotherapy

NCT05507411

Q3 2027

N/ANot yet recruiting

Locally Advanced Colon Cancer

NCT07413146

Phase 2Recruiting

Neoadjuvant

NCT06467799

Clinical

Trials by Indication[1]

Breast Cancer12 trials

MRI in Evaluating Early Response to Chemotherapy in Women With Infiltrating Breast Cancer

Completed·IInstitut Bergonié·N/A·NCT00462696·16 enrolled

Docetaxel, Carboplatin, and Capecitabine as Treatment for Patients With Locally Advanced or Inflammatory Breast Cancer Before Surgery

Unknown status·CCancer Research Network·Phase 2·NCT00251329·48 enrolled

HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer

Active, not recruiting·HH. Lee Moffitt Cancer Center and Research Institute·Phase 1·NCT03387553·31 enrolled

Show 9 more trials

Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 3·NCT06977893·194 enrolled

Study of Neoadjuvant Chemotherapy of Breast Cancer

Unknown status·—·Phase 2·NCT00830544·54 enrolled

Neoadjuvant Aromatase Inhibitor(AI) With Ovarian Suppression Versus Chemotherapy in Premenopausal Breast Cancer Patients

Terminated·RRuijin Hospital·Phase 3·NCT02532400·21 enrolled

Immune Tumor Stroma Factors and Pathologic Complete Response After Neoadjuvant Chemotherapy in Early Breast Cancer

Active, not recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07407244·268 enrolled

Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07254858·302 enrolled

Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)

Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT07383818·111 enrolled

Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer

Unknown status·CChinese Academy of Medical Sciences·Phase 2·NCT02934828·230 enrolled

Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast Cancer: A Single-arm, Prospective Clinical Trial

Recruiting·XXijing Hospital·Phase 2·NCT06914440·27 enrolled

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer

Not yet recruiting·OOhio State University Comprehensive Cancer Center·Preclinical·NCT07217990·84 enrolled

Neoadjuvant Chemotherapy6 trials

Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy

Recruiting·UUniversity Hospital, Rouen·Phase 3·NCT06107920·232 enrolled

Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC

Completed·XXiangya Hospital of Central South University·Phase 2·NCT02876861·74 enrolled

Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell

Unknown status·FFudan University·Phase 2·NCT04520035·60 enrolled

Show 3 more trials

Effect of Neoadjuvant Chemotherapy on MRI Accuracy Before Cystectomy

Recruiting·—·N/A·NCT07202819·76 enrolled

Validity of Sentinel Lymphnode Biopsy After Neoadjuvant Chemotherapy Cancer Patients With Radiologically Positive Axillary Lymph Nodes

Completed·GGangnam Severance Hospital··NCT01622478·120 enrolled

Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer

Not yet recruiting·TThe Catholic University of Korea·N/A·NCT04889820·204 enrolled

Ovarian Cancer5 trials

Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer

Completed·—·Phase 2·NCT01462149·43 enrolled

Total Neoadjuvant 6 Cycles of Chemotherapy Versus 3 Cycles in Partial Responder Patients Diagnosed With Epithelial Ovarian Cancer

Not yet recruiting·—·Phase 3·NCT06980545·50 enrolled

Short-course HIPEC in Advanced Epithelial Ovarian Cancer

Completed·PProfessor Fernando Figueira Integral Medicine Institute·Phase 2·NCT02249013·15 enrolled

Show 2 more trials

SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery

Unknown status·—··NCT06223763·5,000 enrolled

Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer

Unknown status·SShu-Zhong Cui·Phase 3·NCT03180177·263 enrolled

Gastric Cancer5 trials

Neoadjuvant Chemoradiotherapy vs. Chemotherapy Followed by Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer

Completed·SSun Yat-sen University·Phase 3·NCT01815853·620 enrolled

Perioperative Chemotherapy Combined With HIPEC for High-risk Advanced Gastric Cancer

Unknown status·SSixth Affiliated Hospital, Sun Yat-sen University·Phase 3·NCT02960061·640 enrolled

Quality of Life in Advanced Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy

Unknown status·PPeking University Cancer Hospital & Institute··NCT04408859·290 enrolled

Show 2 more trials

AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy

Recruiting·CChinese Academy of Sciences··NCT06035250·200 enrolled

A Comparison of Laparoscopic With Open Distal Gastrectomy in Advanced Gastric Cancer After Neoadjuvant Chemotherapy

Unknown status·PPeking University·Phase 2·NCT02404753·102 enrolled

Cervical Cancer3 trials

Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a Single Center Experience

Terminated·AAzienda Policlinico Umberto I··NCT06752135·97 enrolled

Neoadjuvant Immunochemotherapy for Locally Advanced Cervical Cancer: a Prospective, Single-arm, Phase II Clinical Trial

Recruiting·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·Phase 2·NCT07003620·34 enrolled

Neoadjuvant Chemotherapy in Cervical Cancer

Completed·—·Phase 3·NCT05384366·33 enrolled

36 more indications

Squamous Cell Carcinoma2 trials

RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus

Terminated·MMinistry of Scientific Research and Information Technology, Poland·Phase 3·NCT00559351·84 enrolled

Short Course Neoadjuvant Chemo-radiotherapy Plus Toripalimab for Locally Advanced Resectble Squamous Cell Carcinoma of Esophagus

Unknown status·JJiangsu Cancer Institute & Hospital·Phase 2·NCT05424432·63 enrolled

Locally Advanced Colon Cancer2 trials

Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer

Unknown status·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2/3·NCT02882269·400 enrolled

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Not yet recruiting·SSun Yat-sen University·N/A·NCT07413146·100 enrolled

Colorectal Cancer2 trials

An Exploratory Study of Sequential Transarterial Chemoembolization With Lipiodol and Neoadjuvant Chemotherapy in the Treatment of Initial Unresectable Colorectal Cancer (CRC)

Unknown status·GGang Wu·Phase 2·NCT05340231·100 enrolled

Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT03926338·270 enrolled

Esophageal Squamous Cell Carcinoma2 trials

Patient Derived Organoids (PDOs) to Observe the Clinical Consistency of Personalized Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

Recruiting·SShanghai Zhongshan Hospital··NCT07054086·30 enrolled

Surufatinib in Combination With Neoadjuvant Chemo-immunotherapy and Concurrent Chemoradiotherapy for Patients With Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting·SSun Yat-sen University·Phase 2·NCT07086469·69 enrolled

Lung Cancer2 trials

Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer

Completed·SSpanish Lung Cancer Group·Phase 3·NCT00913705·624 enrolled

Neoadjuvant Immunochemotherapy for Lung Cancer

Completed·SShanghai Zhongshan Hospital··NCT06023797·83 enrolled

Locally-advanced Rectal Cancer2 trials

Neoadjuvant Chemoradiotherapy Plus Sintilimab for MSS, Locally Advanced Rectal Cancer-

Withdrawn·SSun Yat-sen University·Phase 2·NCT06895577

Capecitabine + Irinotecan Followed by Combined Modality Capecitabine and Radiation in Locally Advanced Rectal Cancer

Terminated·—·Phase 2·NCT00216086·22 enrolled

Esophageal Carcinoma2 trials

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

Recruiting·HHenan Cancer Hospital·Phase 3·NCT04280822·400 enrolled

Neoadjuvant Chemotherapy or Chemoradiotherapy in Resectable Oesophageal Carcinoma（NewEC Study）

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University··NCT04027543·423 enrolled

Chemotherapy2 trials

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT05507411·100 enrolled

Feasibility Study of Deep Learning-based MDixon Quant for Quantitative Assessment of Chemotherapy-induced Fatty Liver

Recruiting·YYunnan Cancer Hospital·N/A·NCT06735118·120 enrolled

Bladder Cancer2 trials

Neoadjuvant Chemotherapy for Locally Advanced Gall Bladder Cancer : a Randomized Control Trial (NEOGB)

Recruiting·RRajiv Gandhi Cancer Institute & Research Center, India·Phase 3·NCT06712420·114 enrolled

Neoadjuvant Chemotherapy in Non Muscle Invasive T1b Bladder Cancer

Unknown status·—··NCT04245618·50 enrolled

Observational Study1 trial

Observational Study on Rectal Cancer to Verify if Response After Chemo-radiotherapy Can be Predicted With a Particular Blood Test.

Terminated·DDimitri Christoforidis··NCT03699410·25 enrolled

Hypopharyngeal Carcinoma1 trial

Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma

Not yet recruiting·FFudan University·Phase 3·NCT06957938·168 enrolled

Concurrent Chemoradiotherapy1 trial

Neoadjuvant Chemo-immunotherapy Followed by Concurrent Chemoradiotherapy and Immunotherapy in LACC

Not yet recruiting·RRenJi Hospital·Phase 2·NCT06916117·30 enrolled

Pancreatic Cancer1 trial

NEOadjuvant Gemcitabine/Oxaliplatin Plus Adjuvant Gemcitabine in Resectable PAncreatic Cancer

Completed·IInstitut Paoli-Calmettes·Phase 3·NCT01521702·2 enrolled

Peritoneal Carcinoma1 trial

Trial of Chemotherapy in Ovarian, Fallopian Tube and Peritoneal Carcinoma

Completed·RRachel Miller·Phase 2·NCT01519869·28 enrolled

Adenocarcinoma1 trial

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06831136·24 enrolled

Cytoreductive Surgery1 trial

OVCA-NAC-P2: Study of Chemotherapy Followed by Cytoreductive Surgery for Ovarian, Tubal and Peritoneal Cancers: JCOG0206

Completed·JJapan Clinical Oncology Group·Phase 2·NCT00112086·56 enrolled

Intrahepatic Cholangiocarcinoma1 trial

Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Unknown status·—·Phase 2·NCT04523402·100 enrolled

Osteosarcoma1 trial

A Phase I Clinical Trial of Neoadjuvant Chemotherapy With/Without SPIONs/SMF for Patients With Osteosarcoma

Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT04316091·60 enrolled

Small Cell Lung Cancer1 trial

Neoadjuvant Therapy Combined With Radical Surgery for the Treatment of Small Cell Lung Cancer (SCLC) in II and IIIA Stage

Unknown status·PPeng Zhang·N/A·NCT03523234·300 enrolled

Hepatocellular Carcinoma1 trial

Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma

Active, not recruiting·SSun Yat-sen University·Phase 2·NCT06524466·35 enrolled

Neoadjuvant1 trial

Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC

Recruiting·SSun Yat-sen University·Phase 2·NCT06467799·39 enrolled

Immunochemotherapy1 trial

Neoadjuvant Immunochemotherapy vs Chemoradiotherapy in ESCC

Completed·YYongtao Han·N/A·NCT07236320·200 enrolled

Colon Cancer1 trial

Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers

Recruiting·SSun Yat-sen University·Phase 3·NCT05194878·840 enrolled

Pathological Complete Response1 trial

A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer

Completed·SSun Yat-sen University·Phase 2·NCT06608537·52 enrolled

Nasopharyngeal Carcinoma1 trial

A Multicenter Trial Comparing Multi-course Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

Unknown status·SSun Yat-sen University·Phase 3·NCT00705627·400 enrolled

Chemoradiotherapy1 trial

Adjuvant ChemoRadiotherapy Prior to Surgery in Stage IVa Oral Cancers

Completed·—·Phase 1·NCT03923998·8 enrolled

Neoadjuvant Therapy1 trial

Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC

Recruiting·OObstetrics & Gynecology Hospital of Fudan University·Phase 2·NCT06878222·35 enrolled

Neoadjuvant Treatment1 trial

Neoadjuvant Treatment Real-world Clinical Outcomes in NSCLC

Recruiting·—··NCT05974007·1,500 enrolled

Efficacy and Safety1 trial

Association Between Microbiome and the Efficacy and Safety of PD-1/PD-L1 Blockade in Resectable NSCLC

Not yet recruiting·—··NCT06613308·20 enrolled

Delirium1 trial

Effect of Neoadjuvant Anti-PD-1 Immunotherapy on Perioperative Analgesia and Postoperative Delirium

Completed·TTianjin Medical University Cancer Institute and Hospital··NCT05273827·81 enrolled

Locally Advanced Cervical Cancer1 trial

Cadonilimab in Neoadjuvant Chemotherapy and Maintenance Therapy for Newly Diagnosed, High-risk, Locally Advanced Cervical Cancer :a Multi-center, Prospective, Single-arm Study(CNCMT)

Enrolling by invitation·UUnknown Sponsor·Preclinical·NCT06714084·20 enrolled

Pancreas Cancer1 trial

Neoadjuvant Chemotherapy Followed by Surgery Versus Upfront Surgery for Clearly Resectable Pancreatic Head Cancer and Periampullary Cancer: A Randomized Controlled Trial

Recruiting·MMinia University·Phase 3·NCT07081360·262 enrolled

Gastric Adenocarcinoma1 trial

GI-05: The Impact of Olanzapine Among Patients Receiving Neoadjuvant Chemotherapy for Gastric Cancer

Not yet recruiting·UUniversity of Illinois at Chicago·Phase 2·NCT07581405·26 enrolled

Malignant Neoplasm1 trial

Phase II Trial on the Safety and Efficacy of Partial Cystectomy and Extended Pelvic Lymph Node Dissection With Standard of Care Perioperative Systemic Therapy in the Management of Muscle-Invasive Bladder Cancer (PRESERVE Trial)

Recruiting·CCase Comprehensive Cancer Center·Phase 2·NCT06290687·40 enrolled

Epithelial Ovarian Cancer1 trial

The Feasibility, Safety, and Clinical Outcomes of Fasting During Neoadjuvant Chemotherapy in Patients With Epithelial Ovarian Cancer

Recruiting·CCase Comprehensive Cancer Center·Preclinical·NCT06386887·20 enrolled

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

A Single-arm Phase II Study to Evaluate the Safety and Efficacy of Combination Systematic Chemotherapy and Multiple Rounds of Endoscopic Ultrasound-guided Radiofrequency Ablation in Pancreatic Cancer

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT04990609·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 76 trial records for Neoadjuvant Chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Neoadjuvant Chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Neoadjuvant Chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Japan Clinical Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: JJapan Clinical Oncology Group

Neoadjuvant Chemotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Breast Cancer12 trials

Neoadjuvant Chemotherapy6 trials

Ovarian Cancer5 trials

Gastric Cancer5 trials

Cervical Cancer3 trials

Squamous Cell Carcinoma2 trials

Locally Advanced Colon Cancer2 trials

Colorectal Cancer2 trials

Esophageal Squamous Cell Carcinoma2 trials

Lung Cancer2 trials

Locally-advanced Rectal Cancer2 trials

Esophageal Carcinoma2 trials

Chemotherapy2 trials

Bladder Cancer2 trials

Observational Study1 trial

Hypopharyngeal Carcinoma1 trial

Concurrent Chemoradiotherapy1 trial

Pancreatic Cancer1 trial

Peritoneal Carcinoma1 trial

Adenocarcinoma1 trial

Cytoreductive Surgery1 trial

Intrahepatic Cholangiocarcinoma1 trial

Osteosarcoma1 trial

Small Cell Lung Cancer1 trial

Hepatocellular Carcinoma1 trial

Neoadjuvant1 trial

Immunochemotherapy1 trial

Colon Cancer1 trial

Pathological Complete Response1 trial

Nasopharyngeal Carcinoma1 trial

Chemoradiotherapy1 trial

Neoadjuvant Therapy1 trial

Neoadjuvant Treatment1 trial

Efficacy and Safety1 trial

Delirium1 trial

Locally Advanced Cervical Cancer1 trial

Pancreas Cancer1 trial

Gastric Adenocarcinoma1 trial

Malignant Neoplasm1 trial

Epithelial Ovarian Cancer1 trial

Pancreatic Ductal Adenocarcinoma (PDAC)1 trial

References

Drug Info

Quick Facts

Related News